Integra LifeSciences Holdings Co. (NASDAQ:IART) SVP Jeffrey Mosebrook Sells 279 Shares of Stock

Integra LifeSciences Holdings Co. (NASDAQ:IART – Get Rating) SVP Jeffrey Mosebrook sold 279 shares of the business’s stock in a transaction that occurred on Thursday, December 8th. The stock was sold at an average price of $56.22, for a total transaction of $15,685.38. Following the transaction, the senior vice president now owns 8,552 shares of the company’s stock, valued at approximately $480,793.44. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Integra LifeSciences Trading Up 1.6 %

Shares of Integra LifeSciences stock opened at $56.50 on Friday. The company has a current ratio of 3.93, a quick ratio of 2.91 and a debt-to-equity ratio of 0.86. Integra LifeSciences Holdings Co. has a 12-month low of $40.67 and a 12-month high of $69.95. The firm has a market capitalization of $4.72 billion, a price-to-earnings ratio of 27.43, a PEG ratio of 1.66 and a beta of 1.18. The firm’s 50 day simple moving average is $49.18 and its two-hundred day simple moving average is $51.96.

Integra LifeSciences (NASDAQ:IART – Get Rating) last issued its quarterly earnings results on Wednesday, October 26th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.14. The business had revenue of $385.19 million for the quarter, compared to analyst estimates of $377.79 million. Integra LifeSciences had a net margin of 11.05% and a return on equity of 16.41%. Analysts predict that Integra LifeSciences Holdings Co. will post 3.3 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Jefferies Financial Group assumed coverage on shares of Integra LifeSciences in a research note on Tuesday, October 11th. They set a “hold” rating and a $48.00 price objective for the company. StockNews.com assumed coverage on shares of Integra LifeSciences in a research note on Wednesday, October 12th. They set a “buy” rating for the company. Citigroup reduced their price objective on shares of Integra LifeSciences from $57.00 to $50.00 in a research note on Wednesday, October 5th. Truist Financial reduced their price objective on shares of Integra LifeSciences from $60.00 to $46.00 and set a “hold” rating for the company in a research note on Monday, October 17th. Finally, Piper Sandler reduced their price objective on shares of Integra LifeSciences from $55.00 to $50.00 in a research note on Wednesday, August 24th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $57.38.

Institutional Trading of Integra LifeSciences

Several large investors have recently made changes to their positions in IART. Advisor Group Holdings Inc. boosted its holdings in shares of Integra LifeSciences by 5.3% in the 1st quarter. Advisor Group Holdings Inc. now owns 7,555 shares of the life sciences company’s stock valued at $685,000 after acquiring an additional 381 shares during the last quarter. Teacher Retirement System of Texas boosted its holdings in shares of Integra LifeSciences by 6.6% in the 1st quarter. Teacher Retirement System of Texas now owns 14,911 shares of the life sciences company’s stock valued at $958,000 after acquiring an additional 924 shares during the last quarter. Swiss National Bank boosted its holdings in shares of Integra LifeSciences by 7.4% in the 1st quarter. Swiss National Bank now owns 170,194 shares of the life sciences company’s stock valued at $10,937,000 after acquiring an additional 11,800 shares during the last quarter. Cooke & Bieler LP boosted its holdings in shares of Integra LifeSciences by 6.4% in the 1st quarter. Cooke & Bieler LP now owns 2,529,419 shares of the life sciences company’s stock valued at $162,540,000 after acquiring an additional 152,293 shares during the last quarter. Finally, MQS Management LLC purchased a new stake in shares of Integra LifeSciences in the 1st quarter valued at $365,000. 87.33% of the stock is owned by hedge funds and other institutional investors.

Integra LifeSciences Company Profile

(Get Rating)

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services.